Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CCL5



This biomarker is also known as:
  • small-inducible cytokine A5,
  • t cell-specific protein P228,
  • eosinophil chemotactic cytokine,
  • D17S136E,
  • chemokine (C-C motif) ligand 5,
  • Small-inducible cytokine A5,
  • beta-chemokine RANTES,
  • C-C motif chemokine 5,
  • SISd,
  • small inducible cytokine subfamily A (Cys-Cys), member 5,
  • T-cell specific protein p288,
  • regulated upon activation, normally T-expressed, and presumably secreted,
  • Eosinophil chemotactic cytokine,
  • TCP228,
  • MGC17164,
  • T cell-specific protein P228,
  • SIS-delta,
  • SCYA5,
  • T-cell-specific protein RANTES,
  • small inducible cytokine A5 (RANTES),
  • eoCP,
  • EoCP,

View in BioMuta


CCL5 (RANTES) is a chemokine, a subfamily of cytokines. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. CCL5 is a chemoattractant for blood monocytes, memory T-helper cells and eosinophils and causes the release of histamine from basophils and activates eosinophils. There are several transcript variants that encode different isoforms.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.

Performance Comment

CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.